Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $20.40 Consensus PT from Analysts

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have earned a consensus recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have covered the stock in the last year is $20.40.

A number of research analysts have weighed in on the company. Scotiabank assumed coverage on Protara Therapeutics in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price on the stock. Cantor Fitzgerald began coverage on Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating on the stock. HC Wainwright reissued a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a research report on Monday, April 28th. Finally, Lifesci Capital initiated coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 target price on the stock.

Protara Therapeutics Trading Up 0.9%

Shares of NASDAQ:TARA traded up $0.03 on Friday, reaching $3.27. 283,471 shares of the company traded hands, compared to its average volume of 782,473. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The business's 50-day simple moving average is $3.99 and its 200 day simple moving average is $4.12. The stock has a market capitalization of $126.15 million, a P/E ratio of -1.16 and a beta of 1.73.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.18. Sell-side analysts expect that Protara Therapeutics will post -3.32 EPS for the current fiscal year.

Insider Buying and Selling at Protara Therapeutics

In related news, insider Jacqueline Zummo sold 21,224 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now owns 98,861 shares in the company, valued at $447,840.33. This represents a 17.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.40% of the company's stock.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TARA. Geode Capital Management LLC grew its stake in Protara Therapeutics by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock worth $948,000 after buying an additional 9,553 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Protara Therapeutics in the 1st quarter valued at $64,000. Commonwealth Equity Services LLC raised its stake in shares of Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after buying an additional 17,572 shares during the last quarter. HBK Investments L P purchased a new stake in Protara Therapeutics in the 4th quarter worth approximately $106,000. Finally, Squarepoint Ops LLC acquired a new stake in Protara Therapeutics during the fourth quarter valued at $110,000. Hedge funds and other institutional investors own 38.13% of the company's stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.